OrthoPreserve is developing the first off-the-shelf, anatomically accurate synthetic meniscus implant designed to restore knee function and delay arthritis for patients experiencing persistent symptoms after meniscus surgery. The meniscus is a critical shock absorber and cushion in the knee joint, but the standard of care for meniscus injuries is removal of the damaged tissue – a meniscectomy. Over a million meniscectomies are performed annually, but many patients experience recurring pain and accelerated arthritis development after surgery, yet no FDA‑approved meniscus replacements exist. OrthoPreserve’s minimally invasive, surgeon-friendly device bridges a critical treatment gap to restore a patient’s mobility and preserve their knee joint from additional damage and future knee replacements. Backed by FDA’s Breakthrough Device Designation due to strong preclinical data and its potential to offer a superior treatment option, OrthoPreserve is advancing towards clinical trials with a revolutionary solution for musculoskeletal care.